Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Enhancing cancer immunotherapy by targeted delivery of microbiome-derived molecules
EF 2025-26
Résumé
Cancer immunotherapy has revolutionized treatment for many patients, but many do not respond or the benefit fades. Evidence shows that the right gut microbiome can help the immune system attack tumors. Our previous work shows that lipid extracts from a specific bacterium can lift brakes off the immune system and enhance immunotherapy, specifically in those who do not respond initially. The identity of specific molecules within these bacterial extracts remains unknown, and there is a need to improve their delivery specifically to dendritic cells, a type of immune cells that activate the immune system to attack cancer cells. Our central idea is to discover and test specific components in the extracts of the bacteria, Coprobacillus Cateniformis, and then deliver active molecules in a targeted manner to enhance immunotherapy and avoid widespread immune activation.
First, we will isolate the active lipids from C. cateniformis using stepwise extraction and filtration based on size, charge, and structure. We will select fractions that turn down the brakes on the immune system. Once a specific fraction has been identified, the challenge remains to deliver it to the target immune cell in the body. Nanoparticles can solve this challenge because their properties - size, surface properties, and chemistry - can be tuned to increase uptake into immune cells. We will carry out this screening and develop candidate therapeutic formulations for further testing in mouse models of colon and lung cancers as adjuncts to immunotherapy.
Our work aims to enhance immunotherapy for patients who are currently non-responders. Instead of altering the gut microbiome through invasive transplants, we will discover the underlying mechanism and deliver the therapeutic molecules directly to the immune cells that alter tumor immunity and limit system-wide side effects. By making immunotherapy more efficacious and longer-lasting in more patients, we will improve outcomes across multiple solid tumors.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
Illinois, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537817
Name
Sindhwani Shrey
Region
Illinois
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Enhancing cancer immunotherapy by targeted delivery of microbiome-derived molecules
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Cancer; Drug Delivery; Gut Microbiome; Immunotherapy; Nanomedicine; Tumor Immunology
Abstract
Cancer immunotherapy has revolutionized treatment for many patients, but many do not respond or the benefit fades. Evidence shows that the right gut microbiome can help the immune system attack tumors. Our previous work shows that lipid extracts from a specific bacterium can lift brakes off the immune system and enhance immunotherapy, specifically in those who do not respond initially. The identity of specific molecules within these bacterial extracts remains unknown, and there is a need to improve their delivery specifically to dendritic cells, a type of immune cells that activate the immune system to attack cancer cells. Our central idea is to discover and test specific components in the extracts of the bacteria, Coprobacillus Cateniformis, and then deliver active molecules in a targeted manner to enhance immunotherapy and avoid widespread immune activation.
First, we will isolate the active lipids from C. cateniformis using stepwise extraction and filtration based on size, charge, and structure. We will select fractions that turn down the brakes on the immune system. Once a specific fraction has been identified, the challenge remains to deliver it to the target immune cell in the body. Nanoparticles can solve this challenge because their properties - size, surface properties, and chemistry - can be tuned to increase uptake into immune cells. We will carry out this screening and develop candidate therapeutic formulations for further testing in mouse models of colon and lung cancers as adjuncts to immunotherapy.
Our work aims to enhance immunotherapy for patients who are currently non-responders. Instead of altering the gut microbiome through invasive transplants, we will discover the underlying mechanism and deliver the therapeutic molecules directly to the immune cells that alter tumor immunity and limit system-wide side effects. By making immunotherapy more efficacious and longer-lasting in more patients, we will improve outcomes across multiple solid tumors.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sindhwani, Shrey
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~